fashion -WSS

fashion

author：entertainment 2025-08-12 06:43:24 - browse：73

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Devoted Health’s losses in Medicare Advantage persist

knowledge

WSS

Adults seen as increasingly susceptible to measles

Adopting new red light myopia treatments may be short

Unique patient identifier: Experts argue the benefits, pitfalls

What’s missing from the debate over nursing home staff minimums

Sage hopes for a blockbuster in antidepressant now before FDA

NIH launches clinical trials and new research office for long Covid

focus

fashion

focus

Hollywood unions extend contract negotiations for actors

Adopting new red light myopia treatments may be short

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The Biogen Aduhelm mess could happen again

Alkermes shareholders re

Devoted Health’s losses in Medicare Advantage persist

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Hepatitis C has a cure — but many Americans still lack access to it

Medicare Advantage plans can’t deny care with AI, CMS warns

leisure time

Surgery pushed Ben Carson to fame

Unique patient identifier: Experts argue the benefits, pitfalls

National panel will explore requiring free Covid tests

What’s missing from the debate over nursing home staff minimums

Cano Health’s bankruptcy is a warning for Medicare Advantage

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Wikipedia

focus

knowledge

hotspot